Trial Profile

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ST 01156 (Primary)
Indications Ewing's sarcoma; Haematological malignancies; Solid tumours
Focus Adverse reactions; First in man
Sponsors Seed Therapeutics

Most Recent Events

02 Jun 2026 Trial-in-progress data were presented in the Seed Therapeutics media release.
18 May 2026 According to a SEED Therapeutics media release, company will present data from this study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 through June 2 in Chicago, IL.
13 May 2026 According to SEED Therapeutics media release, company announced the first dose cohort completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com